Investigational drug · Phase 2
Tonlamarsen
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hypertension, Acute Severe Hypertension, Hypertensive Emergency.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "Tonlamarsen"
First trial start
2025
Apr 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tonlamarsen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypertension
- Acute Severe Hypertension
- Hypertensive Emergency
- Hypertensive Urgency
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Tonlamarsen" as an intervention, largest first.
- A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)Pivotal-lookingCompleted
Kardigan, Inc.Industry
NCT06864104 · 206 participants · Start Apr 10, 2025 · Primary completion Jan 12, 2026
Drug: Tonlamarsen; Placebo · For: Hypertension
Sites: Anniston, Alabama; Birmingham, Alabama; Phoenix, Arizona · 39 sites in all
- Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe HypertensionPivotal-lookingRecruiting
Kardigan, Inc.Industry
NCT07511361 · 140 participants (planned) · Start Jun 23, 2026 · Primary completion Dec 2026
Drug: Tonlamarsen; Placebo · For: Hypertension; Acute Severe Hypertension; Hypertensive Emergency and 1 more
Sites: Arvada, Colorado; Homestead, Florida; Port Orange, Florida · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Tonlamarsen-Induced Angiotensinogen Suppression: Does It Underlie Its Blood Pressure-Lowering Effect?
Cruz-López EO, Parvan R, Danser AHJ · JACC Basic Transl Sci 2026
- Tonlamarsen, a Hepatocyte-Directed Antisense Oligonucleotide Targeting Angiotensinogen: Phase 1 and 2a Clinical Studies.
Morgan E, Weinland J, Lin T, et al. · JACC Basic Transl Sci 2026
- Angiotensinogen as a molecular hub in interorgan communication.
Zhou J, Ye X, Wang Y, et al. · J Transl Med 2026
- Angiotensinogen Reconsidered: Evolving Perspectives in Hypertension Research.
Kanbay M, Guldan M, Ozbek L, et al. · Hypertension 2026
- Efficacy of Tonlamarsen in Patients With Uncontrolled Hypertension: The KARDINAL Phase 2 Randomized Clinical Trial.
Laffin LJ, Wang Q, Sarraju A, et al. · J Am Coll Cardiol 2026
Also in development for Hypertension
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
- VCT220CX11Phase 35 trials
Vincentage Pharma Co., Ltd · Obesity, Type 2 Diabetes Mellitus (DM), Hypertension
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- ZilebesiranALN-AGT01Phase 34 trials
Alnylam Pharmaceuticals · Hypertension, High Cardiovascular Risk, High Risk Cardiovascular Disease
- ClazakizumabLY5724886, CSL300Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity
- DWC202314Phase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.